<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936103</url>
  </required_header>
  <id_info>
    <org_study_id>NH-20120404</org_study_id>
    <nct_id>NCT01936103</nct_id>
  </id_info>
  <brief_title>Effects of Intensive Statin Treatment on Left Ventricular Function</brief_title>
  <official_title>Effects of Intensive Statin Therapy on Left Ventricular Function for Patients With the First Acute Anterior Myocardial Infarction After Directly to Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First acute anterior myocardial infarction in patients with primary PCI preoperative and
      postoperative 30 days intensive dose atorvastatin statin therapy compared with conventional
      -dose therapy , patients can improve left ventricular function , reduce major adverse
      cardiovascular events .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonic observation of left ventricular end-diastolic diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonic observation of left ventricular end-systolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonic observation of left ventricular fractional shortening RWSI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonic observation of the left ventricular ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>30 days</time_frame>
    <description>ultrasonic observation of E/A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the left ventricular function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the left ventricular function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma brain natriuretic peptide</measure>
    <time_frame>30days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma brain natriuretic peptide</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma brain natriuretic peptide</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>enzymes</measure>
    <time_frame>1 year</time_frame>
    <description>the level of CK peak</description>
  </other_outcome>
  <other_outcome>
    <measure>Major adverse cardiac and cerebral events at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>1 year after death, cardiac death , myocardial infarction , heart failure , cardiac causes hospitalization , revascularization combined endpoint of cerebrovascular events .</description>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>1 year</time_frame>
    <description>Aspartate aminotransferase (AST) returned to normal in the perioperative period</description>
  </other_outcome>
  <other_outcome>
    <measure>enzymes</measure>
    <time_frame>1 year</time_frame>
    <description>CK-MB peak</description>
  </other_outcome>
  <other_outcome>
    <measure>enzymes</measure>
    <time_frame>1 year</time_frame>
    <description>troponin (TnT)</description>
  </other_outcome>
  <other_outcome>
    <measure>enzymes</measure>
    <time_frame>1 year</time_frame>
    <description>CK-MB peak time</description>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>1 year</time_frame>
    <description>any elevation&gt; 3 times the proportion</description>
  </other_outcome>
  <other_outcome>
    <measure>alanine aminotransferase (ALT)</measure>
    <time_frame>1 year</time_frame>
    <description>alanine aminotransferase (ALT)returned to normal in the perioperative period</description>
  </other_outcome>
  <other_outcome>
    <measure>alanine aminotransferase (ALT)</measure>
    <time_frame>1 year</time_frame>
    <description>any elevation&gt; 3 times the proportion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Anterior Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard group</intervention_name>
    <description>standard statin treatment:Atorvastatin statins 20mg / night .</description>
    <arm_group_label>standard group</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intensive group</intervention_name>
    <description>intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation</description>
    <arm_group_label>intensive group</arm_group_label>
    <other_name>intensive Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years of age

          2. the first time clinical diagnosis of acute anterior myocardial infarction , the time
             of onset ≤ 12 hours ,intends underwent emergency PCI

          3. informed consent

        Exclusion Criteria:

          1. Taking , or the need for long-term use of statins is greater than the initial dose

          2. treated with PCI again within a mouth

          3. active liver disease or liver dysfunction

          4. the diagnosis of myopathy

          5. severe renal insufficiency ( serum creatinine &gt; 178umol / L )

          6. Statin drug allergy or had a serious adverse reaction

          7. severe aortic stenosis or mitral stenosis , hypertrophic obstructive cardiomyopathy ,
             pericardial disease

          8. pregnancy

          9. malignancy or any other end-stage diseases result in a life expectancy of &lt; 6 months

         10. be participating in other clinical studies

         11. not suitable for inclusion of the other cases

         12. not treated with PCI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geng Wang, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geng Wang, Dr</last_name>
    <phone>+86-24-28897280</phone>
    <email>Wanggeng69@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenyang Northen Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Geng, Dr</last_name>
      <phone>13309886393</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>September 2, 2013</last_update_submitted>
  <last_update_submitted_qc>September 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling, MD</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <keyword>Acute anterior myocardial infarction</keyword>
  <keyword>Percutaneous coronary stent implantation</keyword>
  <keyword>Intensive statin therapy</keyword>
  <keyword>Left ventricular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

